» Articles » PMID: 31488063

Long-term Adherence to Antiretroviral Therapy in a South African Adult Patient Cohort: a Retrospective Study

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2019 Sep 7
PMID 31488063
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Background: South Africa has the highest HIV prevalence and supports the largest antiretroviral therapy (ART) programme globally. With the introduction of a test and treat policy, ensuring long term optimal adherence to ART (≥95%) is essential for successful patient and public health outcomes. The aim of this study was to assess long-term ART adherence to inform best practices for chronic HIV care.

Method: Long-term ART adherence was retrospectively analysed over a median duration of 5 years (interquartile range [IQR]: 5.3-6.5) in patients initially enrolled in a randomised controlled trial assessing tuberculosis and HIV treatment integration and subsequently followed post-trial in an observational cohort study in Durban, South Africa. The association between baseline patient characteristics and adherence over time was estimated using generalized estimating equations (GEE). Adherence was assessed using pharmacy pill counts conducted at each study visit and compared to 6 monthly viral load measurements. A Kaplan Meier survival analysis was used to estimate time to treatment failure. The McNemar test (with exact p-values) was used to determine the effect of pill burden and concurrent ART and tuberculosis treatment on adherence.

Results: Of the 270 patients included in the analysis; 54.8% were female, median age was 34 years (IQR:29-40) and median time on ART was 70 months (IQR = 64-78). Mean adherence was ≥95% for each year on ART. Stable patients provided with an extended 3-month ART supply maintained adherence > 99%. At study end, 96 and 94% of patients were optimally adherent and virologically suppressed, respectively. Time since ART initiation, female gender and primary breadwinner status were significantly associated with ≥95% adherence to ART. The cumulative probability of treatment failure was 10.7% at 5 years after ART initiation. Concurrent ART and tuberculosis treatment, or switching to a second line ART regimen with higher pill burden, did not impair ART adherence.

Conclusion: Optimal long-term adherence with successful treatment outcomes are possible within a structured ART programme with close adherence monitoring. This adherence support approach is relevant to a resource limited setting adopting a test and treat strategy.

Citing Articles

Viral Suppression and HIV Drug Resistance Among Patients on Second-Line Antiretroviral Therapy in Selected Health Facility in Ethiopia.

Zealiyas K, Gebreegziabxier A, Getaneh Y, Kidane E, Woldesemayat B, Yizengaw A Viruses. 2025; 17(2).

PMID: 40006960 PMC: 11860432. DOI: 10.3390/v17020206.


Evaluation of Treatment Outcomes Among Individuals on Highly Active Antiretroviral Therapy in KwaZulu-Natal, South Africa.

Muzumbukilwa T, Manimani R, Mushebenge A, Vagiri R, Nlooto M AIDS Res Treat. 2024; 2024:8834740.

PMID: 39691492 PMC: 11651757. DOI: 10.1155/arat/8834740.


Evaluating compliance with quality indicators of HIV and AIDS clinical care and analyzing those associated with mortality in the Democratic Republic of Congo.

Muzumbukilwa T, Dieudonne B, Manimani R, Mushebenge A, Vagiri R, Nlooto M BMC Infect Dis. 2024; 24(1):1359.

PMID: 39609662 PMC: 11603654. DOI: 10.1186/s12879-024-10253-y.


Prevalence and correlates of common mental disorders in people living with HIV in primary health care facilities in Ekurhuleni district.

Edet A, Agbo S, Amodu A, Edet N Afr J Prim Health Care Fam Med. 2024; 16(1):e1-e11.

PMID: 39501856 PMC: 11538095. DOI: 10.4102/phcfm.v16i1.4568.


'Not taking medications and taking medication, it was the same thing:' perspectives of antiretroviral therapy among people hospitalised with advanced HIV disease.

Loveday M, Hlangu S, Manickchund P, Govender T, Furin J BMC Infect Dis. 2024; 24(1):819.

PMID: 39138390 PMC: 11320996. DOI: 10.1186/s12879-024-09729-8.


References
1.
Bangsberg D, Hecht F, Charlebois E, Zolopa A, Holodniy M, Sheiner L . Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000; 14(4):357-66. DOI: 10.1097/00002030-200003100-00008. View

2.
Paterson D, Swindells S, Mohr J, BRESTER M, Vergis E, Squier C . Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133(1):21-30. DOI: 10.7326/0003-4819-133-1-200007040-00004. View

3.
Gao X, Nau D, ROSENBLUTH S, Scott V, Woodward C . The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care. 2000; 12(4):387-98. DOI: 10.1080/09540120050123783. View

4.
Bangsberg D, Perry S, Charlebois E, Clark R, Roberston M, Zolopa A . Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001; 15(9):1181-3. DOI: 10.1097/00002030-200106150-00015. View

5.
Orrell C, Bangsberg D, Badri M, Wood R . Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS. 2003; 17(9):1369-75. DOI: 10.1097/00002030-200306130-00011. View